SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Business
Has Gilead Finally Bottomed Out?
May 9, 2017
 · 
1 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Biotech Bay
This New Threat Could Cause Gilead to Hit Bottom
May 5, 2017
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Biotech Bay
Gilead Hints at 5-Point Comeback Strategy
May 4, 2017
 · 
4 min read
Drug Development
Why Gilead Should Pay Close Attention And Maybe Even Fear Allergan’s NASH Program
April 25, 2017
 · 
1 min read
Biotech Bay
Gilead: A Future Dividend Gold Mine At A Bargain Price
April 25, 2017
 · 
1 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Business
Gilead’s $600 Million NASH Deal Finally Bears Fruit
April 24, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
How This Iowa Biotech Could be a Perfect Match for M&A Hungry Gilead
April 24, 2017
 · 
3 min read
Business
Gilead’s Rumored M&A Target Incyte Doubled CEO’s Pay Package in 2016
April 18, 2017
 · 
1 min read
Drug Development
How AbbVie, Gilead, Pfizer Are All Gaining From Eli Lilly’s RA Rejection Pain
April 18, 2017
 · 
1 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
Gilead Announces New License Agreement With The Medicines Patent Pool For Access To Bictegravir
October 4, 2017
 · 
4 min read
Deals
Gilead Completes Tender Offer For All Outstanding Shares Of Kite Pharma
October 3, 2017
 · 
5 min read
Deals
Gilead Completes Acquisition Of Kite Pharma
October 3, 2017
 · 
5 min read
Business
Gilead’s Longtime COO To Retire, Effectively Early 2018
September 28, 2017
 · 
3 min read
Deals
Gilead And Kite Pharma Announce Expiration Of Hart-Scott-Rodino Waiting Period
September 26, 2017
 · 
5 min read
FDA
China Food And Drug Administration Approves Gilead’s Sovaldi (Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Infection
September 25, 2017
 · 
7 min read
Biotech Bay
Gilead Prices $3 Billion Of Senior Unsecured Notes
September 15, 2017
 · 
4 min read
Biotech Bay
Gilead Release: U.S. FDA Approves Expanded Labeling For Epclusa (Sofosbuvir/Velpatasvir) For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV
August 2, 2017
 · 
7 min read
Biotech Bay
European Commission (EC) Grants Marketing Authorization For Gilead’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Genotypes Of Chronic Hepatitis C
July 28, 2017
 · 
8 min read
Business
Gilead Announces Second Quarter 2017 Financial Results
July 27, 2017
 · 
1 min read
Load More